Related Experiment Videos
A lipoxygenase inhibitor from Aspergillus niger
Rao K C Sekhar1, Divakar K C Sekhar, Rao A G Appu
1Fermentation Technology and Bioengineering Department, Central Food Technological Research Institute, Mysore, India.
Applied Microbiology and Biotechnology
|April 17, 2002
Summary
Researchers isolated a novel bisphenol-derivative inhibitor from Aspergillus niger CFTRI 1105. This compound effectively inhibits lipoxygenase-1 (LOX-1), offering potential for new therapeutic applications.
Area of Science:
- Biochemistry
- Natural Product Chemistry
- Enzymology
Background:
- Lipoxygenase-1 (LOX-1) is an enzyme implicated in inflammatory pathways.
- Inhibitors of LOX-1 are of therapeutic interest for inflammatory diseases.
- Natural products offer a rich source for novel enzyme inhibitors.
Purpose of the Study:
- To isolate and characterize a novel inhibitor of lipoxygenase-1 (LOX-1) from a microbial source.
- To elucidate the chemical structure of the isolated inhibitor.
- To evaluate the inhibitory activity of the compound against soybean LOX-1 and compare it with known analogues.
Main Methods:
- Fermentation of Aspergillus niger CFTRI 1105.
- Purification using column chromatography and preparative thin layer chromatography.
- Structure elucidation via 1H NMR and Gas Chromatography-Mass Spectrometry (GC-MS).
- Enzyme inhibition assays using soybean LOX-1.
Main Results:
- Isolation and purification of a bisphenol-derivative inhibitor.
- Determination of the inhibitor's structure as 2-(2 -methyl, 4 -hydroxyphenyl), 2-(4"hydroxyphenyl)-propane (MW 242, C16H18O2).
- The inhibitor demonstrated 50% inhibition of soybean LOX-1 at a concentration of 0.98 mM.
- Comparative analysis with bisphenol A, butylhydroxyanisole, and butylhydroxytoluene.
Conclusions:
- A novel LOX-1 inhibitor was successfully isolated from Aspergillus niger.
- The identified bisphenol derivative exhibits significant inhibitory activity against LOX-1.
- Understanding the structure-activity relationship of this inhibitor can guide the development of new anti-inflammatory agents.